Merus N.V. announced on June 4, 2025, the pricing of an underwritten public offering of 5,263,158 common shares at a public offering price of $57.00 per share. The gross proceeds from the offering are expected to be approximately $300.0 million, excluding the underwriters’ option to purchase additional shares.
Merus also granted the underwriters a 30-day option to purchase up to an additional 789,473 common shares. The offering is expected to close on or about June 5, 2025, subject to customary closing conditions.
The company intends to use the net proceeds from this offering, along with its existing capital, to advance the clinical development of its product candidates, for preclinical research and technology development, and for working capital and general corporate purposes. This capital infusion significantly bolsters Merus's financial runway to support its ambitious pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.